Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1681-1690 of 1,873) with videos related to

Pageof 188
Sort By:
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureScott D Solomon, John W Ostrominski, Xiaowen Wang, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HFCarly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
European Heart Journal Open|January 15, 2026
Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trialCaroline Espersen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
NEJM Evidence|February 6, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER TrialsToru Kondo, Samvel B Gasparyan, Pardeep S Jhund, et al.
Pageof 188

Showing results (1681-1690 of 1,873) with videos related to

Sort By:
Pageof 188
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureScott D Solomon, John W Ostrominski, Xiaowen Wang, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HFCarly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
European Heart Journal|August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypesMichele Senni, Walter J Paulus, Antonello Gavazzi, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
European Heart Journal Open|January 15, 2026
Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trialCaroline Espersen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
NEJM Evidence|February 6, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER TrialsToru Kondo, Samvel B Gasparyan, Pardeep S Jhund, et al.
Pageof 188